These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21613254)

  • 1. How I treat primary CNS lymphoma.
    Ferreri AJ
    Blood; 2011 Jul; 118(3):510-22. PubMed ID: 21613254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Present and future treatment options for primary CNS lymphoma.
    Citterio G; Reni M; Ferreri AJ
    Expert Opin Pharmacother; 2015; 16(17):2569-79. PubMed ID: 26371872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
    Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy.
    Lachance DH; Brizel DM; Gockerman JP; Halperin EC; Burger PC; Boyko OB; Brown MT; Schold SC
    Neurology; 1994 Sep; 44(9):1721-7. PubMed ID: 7936304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
    Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
    Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
    [No Abstract]   [Full Text] [Related]  

  • 6. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNS lymphoma.
    Chamberlain MC
    Neurology; 1995 Jun; 45(6):1233. PubMed ID: 7783902
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
    Holte H; Leppä S; Björkholm M; Fluge O; Jyrkkiö S; Delabie J; Sundström C; Karjalainen-Lindsberg ML; Erlanson M; Kolstad A; Fosså A; Ostenstad B; Löfvenberg E; Nordström M; Janes R; Pedersen LM; Anderson H; Jerkeman M; Eriksson M
    Ann Oncol; 2013 May; 24(5):1385-92. PubMed ID: 23247661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary CNS lymphoma.
    Ferreri AJ; Marturano E
    Best Pract Res Clin Haematol; 2012 Mar; 25(1):119-30. PubMed ID: 22409828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
    Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
    Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
    Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
    J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of lymphoma with respect to pathologic classification: updates and controversies].
    Zhu J; Song YQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):724-7. PubMed ID: 20079009
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Primary lymphoma of the bladder: a case report].
    Statoua M; Mokrim M; El Ghanmi J; Karmouni T; El Khadir K; Koutani A; Attya AI; Errihani H
    Pan Afr Med J; 2014; 18():148. PubMed ID: 25419286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
    Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
    J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.